IE
BCAB icon

Israel Englander’s BioAtla BCAB Stock Holding History

Israel Englander’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,404
Closed -$579K – 6360
2022
Q4 		$579K Buy
+1,404
New +$582K ﹤0.01% 4629

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Israel Englander's BCAB Position: Q2 2026 in Review

Israel Englander increased its BioAtla (BCAB) stake by 28% in Q2 2026, buying an estimated $65.6K and bringing the position to 70,616 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #5125.

Israel Englander first reported a position in BCAB in Q4 2020 and has held it in 21 quarters since. The position peaked at $11.1M in Q4 2020. 21 funds tracked by Wall St. Rank hold BCAB as of Q2 2026.

  • Israel Englander held 70,616 shares of BioAtla worth $292K as of Q2 2026.
  • Israel Englander bought 15,483 BioAtla shares in Q2 2026, an estimated $65.6K.
  • BioAtla made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5125 holding.
  • Israel Englander first reported a position in BioAtla in Q4 2020 and has held it in 21 quarters since.
  • Israel Englander's BioAtla position peaked at $11.1M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held BioAtla as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.